Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study of Nicotinamide Riboside Supplementation in Allogeneic Hematopoietic Cell Transplantation
Sponsor: Case Comprehensive Cancer Center
Summary
The purpose of this study is to find a safe and tolerable way to improve engraftment after transplant. Research studies have shown that adding nicotinamide riboside to donor cells has the potential to increase blood stem cell numbers and potentially decrease the time to engraftment. Also, nicotinamide riboside, TRU NIAGEN (the study drug) is a type of vitamin B supplement that the general public can get without a prescription and is well tolerated.
Official title: A Pilot Study of Nicotinamide Riboside Supplementation in Allogeneic Hematopoietic Cell Transplantation
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
20
Start Date
2020-05-19
Completion Date
2026-09
Last Updated
2026-02-18
Healthy Volunteers
No
Interventions
Nicotinamide riboside (NR)
Nicotinamide riboside, PO, 500mgtwice daily for 21, 28, and 35 days
Locations (1)
Cleveland Clinic, Case Comprehensive Cancer Center
Cleveland, Ohio, United States